Sofosbuvir
- Generic Name
- Sofosbuvir
- Brand Names
- Epclusa, Harvoni, Sovaldi, Vosevi
- Drug Type
- Small Molecule
- Chemical Formula
- C22H29FN3O9P
- CAS Number
- 1190307-88-0
- Unique Ingredient Identifier
- WJ6CA3ZU8B
- Background
Sofosbuvir (tradename Sovaldi) is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, ...
- Indication
Sofosbuvir is used in combination therapy with other antiviral medications to treat chronic hepatitis C virus (HCV) infected patients with HCV genoptypes 1-6, and to treat HCV and HIV co-infected patients. Depending on the level of cirrhosis or decompensation, combination therapy can also include either ribavirin alone or ribavirin and peg-interferon alfa.
...
- Associated Conditions
- Chronic Hepatitis C - Genotype 3, Chronic Hepatitis C Genotype 1, Chronic Hepatitis C Virus (HCV) Infection, Chronic hepatitis C genotype 1a, Chronic hepatitis C genotype 2, Chronic hepatitis C genotype 5, Genotype 4 Chronic Hepatitis C, Genotype 6 chronic hepatitis C infection
- Associated Therapies
- -
Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy
- Conditions
- Interventions
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 15
- Registration Number
- NCT05717400
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Direct Acting Anti-Viral's In Chronic HCV Patients
- Conditions
- First Posted Date
- 2020-12-11
- Last Posted Date
- 2020-12-11
- Lead Sponsor
- Getz Pharma
- Target Recruit Count
- 511
- Registration Number
- NCT04664894
- Locations
- 🇵🇰
Liver Center Faisalabad, Faisalabad, Punjab, Pakistan
Sofosbuvir Containing Regimens in Treatment of COVID 19 Patients
- First Posted Date
- 2020-08-04
- Last Posted Date
- 2020-12-03
- Lead Sponsor
- Tanta University
- Target Recruit Count
- 100
- Registration Number
- NCT04497649
- Locations
- 🇪🇬
Cairo and Tanta Universitities, Tanta, Egypt
Sofosbuvir in Treatment of COVID 19
- First Posted Date
- 2020-07-07
- Last Posted Date
- 2020-12-08
- Lead Sponsor
- Tanta University
- Target Recruit Count
- 60
- Registration Number
- NCT04460443
- Locations
- 🇪🇬
Sherief Abd-Elsalam, Tanta, Egypt
Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Sofosbuvir in Treatment-naïve Patients With Chronic Hepatitis C Genotype 1
- Conditions
- Interventions
- First Posted Date
- 2020-01-29
- Last Posted Date
- 2022-10-31
- Lead Sponsor
- R-Pharm
- Target Recruit Count
- 85
- Registration Number
- NCT04246723
- Locations
- 🇷🇺
FBIS CSRI of Epidemiology of Federal Service on Customers, Moscow, Russian Federation
🇷🇺FSIS FRC of food and biotechnology, Moscow, Russian Federation
🇷🇺SBEI HPE MSMDU n.a. A.I. Evdokimov of Ministry of Health of Russia, Moscow, Russian Federation
Study of Seraprevir in Combination With Sofosbuvir in Chronic Genotype 2,3,6 Hepatitis C Virus Infection Patients
- First Posted Date
- 2019-10-01
- Last Posted Date
- 2019-10-01
- Lead Sponsor
- Ginkgopharma CO., LTD
- Target Recruit Count
- 36
- Registration Number
- NCT04111367
- Locations
- 🇨🇳
Liuzhou General Hospital, Liuzhou, Guangxi Zhuang Autonomous Region, China
🇨🇳The first hospital of JILIN University., Changchun, Jilin, China
🇨🇳Beijing Ditan Hospital,Capital Medical University, Beijing, Beijing, China
Study of Seraprevir in Combination With Sofosbuvir in Chronic Genotype 1 Hepatitis C Virus Infection Patients
- First Posted Date
- 2019-06-28
- Last Posted Date
- 2019-06-28
- Lead Sponsor
- Ginkgopharma CO., LTD
- Target Recruit Count
- 206
- Registration Number
- NCT04001608
- Locations
- 🇨🇳
The First Affiliated Hospital Of Guangxi Medical University, Guangxi, Nanning, China
🇨🇳Traditional Chinese Medical Hospital Affiliated To Southwest Medical University, Luzhou, Sichaun, China
🇨🇳The First Hospital Of Hebei Medical University, Shijiazhuang, Hebei, China
KW-136 With Sofosbuvir for Chinese Adults With Chronic Hepatitis C
- First Posted Date
- 2019-06-24
- Last Posted Date
- 2019-06-25
- Lead Sponsor
- Kawin Technology Share-holding Co., Ltd.
- Target Recruit Count
- 371
- Registration Number
- NCT03995485
- Locations
- 🇨🇳
Chinese PLA 302 Hospital, Beijing, Beijing, China
🇨🇳Capital Medical University Affiliated Beijing Youyi Hospital, Beijing, Beijing, China
🇨🇳Sun Yat-sen University Affiliated Third University, Guangzhou, Guangdong, China
Safety of Sofosbuvir in People With Advanced Kidney Failure
- Conditions
- Interventions
- First Posted Date
- 2019-03-21
- Last Posted Date
- 2021-04-06
- Target Recruit Count
- 30
- Registration Number
- NCT03883698
- Locations
- 🇮🇳
Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India
Study to Evaluate the Safety and PK of Elpida® in Healthy Subjects and Patients With Hepatic Impairment and to Assess the Impact of Food Intake and Drug-Drug Interactions With Other Antiviral Drugs
- Conditions
- Interventions
- First Posted Date
- 2018-10-16
- Last Posted Date
- 2022-01-11
- Lead Sponsor
- Viriom
- Target Recruit Count
- 36
- Registration Number
- NCT03706898
- Locations
- 🇷🇺
Regional State Budgetary Healthcare Institution "Smolensk Regional Clinical Hospital", Smolensk, Russian Federation
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.